Home / Insights / Can a Blood Test Detect Alzheimer’s Disease?

Diagnosis & Biomarkers

Can a Blood Test Detect Alzheimer’s Disease?

A blood draw can now provide clinically useful evidence of Alzheimer-related brain pathology — but it is not a stand-alone answer to every memory complaint.

7–9 minute read

For decades, confirming the biology of Alzheimer’s disease usually meant looking for amyloid with a PET scan or measuring amyloid and tau proteins in cerebrospinal fluid collected by lumbar puncture. Blood-based biomarkers are changing that equation. Some newer tests can detect biochemical signals that closely track Alzheimer’s pathology, and in 2025 the U.S. Food and Drug Administration cleared the first blood test intended to aid diagnosis in certain symptomatic adults.

That does not mean Alzheimer’s can now be diagnosed from a single vial of blood in the same way a glucose test can identify diabetes. The key question is more precise: can a blood test provide reliable evidence that Alzheimer-related amyloid or tau pathology is present? For selected patients, the answer is increasingly yes — when the right test is used, in the right clinical setting, and interpreted alongside symptoms, cognitive assessment, medical history, and other relevant findings.

What exactly is the blood test looking for?

The most useful Alzheimer’s blood tests do not search for a single “Alzheimer’s molecule.” Instead, they measure proteins or protein fragments that reflect biological processes occurring in the brain. The two central pathways are amyloid-beta and tau — the same hallmark pathologies used in modern biological frameworks of Alzheimer’s disease.

One biomarker has attracted particular attention: phosphorylated tau 217, usually shortened to p-tau217. Tau is a normal neuronal protein, but in Alzheimer’s disease its phosphorylation pattern changes in association with amyloid and tau pathology. Multiple studies have found that plasma p-tau217 performs particularly well for identifying people who are likely to have Alzheimer’s-type amyloid pathology and, in some settings, abnormal tau as well.

Other blood measures include p-tau181, p-tau231, amyloid-beta ratios such as Aβ42/Aβ40, and combinations of markers. Different assays are not interchangeable. They use different technologies, cutoffs, algorithms, and intended populations, so the phrase “an Alzheimer’s blood test” can be misleading if it implies that every commercially available test has the same accuracy.

What it reflects	Clinical role today
p-tau217	Among the best-performing blood markers in current studies; used in validated diagnostic assays
p-tau181 / p-tau231	Useful in some assays, but performance varies by platform and setting
Aβ42/Aβ40 or related amyloid measures	Can add information about amyloid pathology; often used in combination with tau markers

What changed in 2025?

On May 16, 2025, the FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, the first blood-based in vitro diagnostic device cleared in the United States to aid in diagnosing Alzheimer’s disease. Its intended use is specific: adults age 55 and older who have signs and symptoms of cognitive decline and are being evaluated in a specialized care setting.

The assay measures plasma p-tau217 and amyloid-beta 1-42 and calculates a ratio associated with the presence or absence of amyloid plaques. In the clinical data reviewed by the FDA, positive and negative results showed strong agreement with amyloid PET or cerebrospinal-fluid testing. The agency also emphasized an equally important limitation: the test is not intended as a screening test or as a stand-alone diagnosis.

Where blood tests fit in the diagnostic pathway

A useful way to think about blood biomarkers is as part of a diagnostic pathway rather than as a verdict. A clinician first establishes whether there is objective cognitive impairment and considers other explanations. Depending on the presentation, that may involve a neurological examination, cognitive testing, medication review, laboratory studies, structural brain imaging, and assessment for conditions such as depression, sleep disorders, vascular disease, delirium, or metabolic abnormalities.

If Alzheimer’s disease remains a plausible cause, a validated blood biomarker can help estimate whether Alzheimer-type pathology is present. The 2025 Alzheimer’s Association clinical practice guideline for specialty care uses a performance-based approach. It states that high-sensitivity blood tests can be used for triage in people with objective cognitive impairment; a negative result may make Alzheimer’s pathology unlikely, while a positive triage result should be confirmed by another method. Tests meeting higher thresholds for both sensitivity and specificity may, in appropriate specialty-care settings, serve as a substitute for amyloid PET or cerebrospinal-fluid biomarker testing.

This is a major shift because PET imaging is expensive and not universally available, while lumbar puncture is more invasive than a routine blood draw. A reliable blood test can reduce barriers, shorten the diagnostic pathway, and help identify patients who may need confirmatory testing or consideration for disease-modifying therapy.

Can a positive blood test diagnose Alzheimer’s by itself?

No. A positive biomarker indicates that Alzheimer-related pathology is likely present; it does not automatically prove that Alzheimer’s disease is the sole cause of a person’s symptoms. Older adults commonly have mixed brain pathology. Vascular injury, Lewy body disease, medication effects, sleep disorders, depression, and other conditions may coexist with amyloid or tau abnormalities.

The reverse is also important. A negative result from a well-validated test can make Alzheimer’s pathology less likely, but it does not explain the cognitive symptoms. The diagnostic task then shifts toward other causes.

Why p-tau217 has become so important

Among the blood biomarkers studied so far, p-tau217 has repeatedly shown high diagnostic performance. A 2024 JAMA study involving patients with cognitive symptoms in primary and secondary care reported about 90% diagnostic accuracy for a p-tau217-based approach against a biological Alzheimer’s reference standard. A separate JAMA Neurology study found that a commercially available plasma p-tau217 assay identified biological Alzheimer’s disease with performance approaching established cerebrospinal-fluid biomarkers.

Head-to-head comparisons also suggest that p-tau217-based measures generally outperform several other blood biomarkers for classifying amyloid and tau status. That does not make p-tau217 infallible. Accuracy depends on the assay, cutoff strategy, population, laboratory quality, kidney function and other biological variables, and the probability of Alzheimer’s disease before the test is ordered.

Why “90% accurate” does not mean “90% certain for everyone”

Diagnostic accuracy is often compressed into a headline number, but individual interpretation depends on context. A test can perform very differently in a memory clinic full of patients with objective cognitive impairment than it would in a younger, symptom-free population. The chance that a positive result truly represents disease depends partly on how likely the disease was before testing — a concept called pretest probability.

This is one reason expert guidance currently centers blood biomarkers on people who already have objective cognitive impairment and are being evaluated clinically. Testing large numbers of healthy, asymptomatic adults would create a different balance of true positives, false positives, uncertain findings, psychological consequences, and follow-up testing.

What about FDA clearance, approval, and commercial tests?

Medical-test terminology matters. The first U.S. blood test described above was FDA-cleared through the 510(k) pathway; “cleared” is the correct regulatory term for that device. Other laboratory-developed or commercially marketed blood biomarker tests may be available, but availability does not mean every test has undergone the same FDA review or meets the same clinical-performance thresholds.

There is also a current regulatory detail worth noting. As of August 10, 2026, the FDA recall database lists an open Class II recall/product correction involving specified lots of Lumipulse G pTau217 Plasma Calibrators used with the pTau217/β-Amyloid 1-42 Plasma Ratio because of a risk of falsely elevated results. The notice applies to identified lots and directs affected laboratories to discontinue those lots and review prior results as appropriate. This illustrates why laboratory quality control and current regulatory information matter even after a diagnostic platform enters clinical use.

Could blood testing replace PET scans and lumbar punctures?

In some diagnostic situations, high-performing blood tests may reduce or even replace the need for amyloid PET or cerebrospinal-fluid biomarkers. The 2025 Alzheimer’s Association guideline explicitly allows that possibility for assays that meet stringent sensitivity and specificity thresholds in specialty care. But replacement is not universal.

PET imaging can show the anatomical distribution and burden of amyloid or tau, while cerebrospinal fluid provides a broader biochemical profile. Blood testing is simpler, but different clinical questions may still require different tools. Imaging is also important for evaluating structural disease, vascular injury, tumors, hydrocephalus, and treatment-related safety issues; a blood biomarker cannot perform those functions.

Why blood biomarkers matter more now than five years ago

The diagnostic value of biomarkers has changed because treatment has changed. Disease-modifying anti-amyloid therapies are intended for selected patients in early symptomatic stages and require confirmation of amyloid pathology before treatment. A more accessible blood-based route to demonstrating that pathology can make the evaluation process faster and potentially more scalable.

Blood tests may also improve clinical-trial recruitment and research by identifying participants more efficiently. Over time, they may help researchers track biological change or treatment response. Those applications are developing rapidly, but a research use should not automatically be assumed to be a validated routine clinical use.

What a blood test cannot tell you

Even an excellent biomarker has boundaries. A blood test cannot, by itself, tell a family exactly how fast cognitive decline will progress. It cannot determine every cause of confusion or memory loss. It cannot replace a neurological history, determine whether a person is safe to drive, assess decision-making capacity, or show how much support someone needs at home.

It also cannot be interpreted in isolation from age, symptoms, disease stage, other illnesses, medications, laboratory factors, and the specific assay used. The clinical value comes from combining a biological signal with the patient’s real-world presentation.

What a validated blood biomarker may help answer	What it cannot answer alone
Is Alzheimer-type pathology likely present?	It does not establish the full cause of cognitive symptoms
Is more testing needed?	It cannot choose every next step without clinical context
How fast will disease progress?	It cannot provide an individual timeline
Should treatment begin?	Treatment decisions also require stage, safety, eligibility, preferences, and monitoring

Frequently asked questions

Can I ask my primary-care doctor for an Alzheimer’s blood test?

Availability varies. Current evidence-based guidance is strongest for people with objective cognitive impairment who are being evaluated in specialty or structured clinical care. A clinician can determine whether a blood biomarker is appropriate and which assay has adequate validation.

Can a healthy person use a blood test to see whether Alzheimer’s will develop later?

Routine population screening of asymptomatic people is not the current intended use of the FDA-cleared test described here, and the 2025 specialty-care guideline focuses on patients with objective cognitive impairment. Research on preclinical detection is active, but clinical use requires careful consideration of what a result would mean and what action would follow.

Does a positive test mean dementia is inevitable?

No. Biomarker positivity and clinical dementia are not the same thing. Biological Alzheimer’s changes can precede dementia, and symptoms depend on disease burden, other brain pathology, cognitive reserve, and many individual factors.

Are all Alzheimer’s blood tests equally reliable?

No. Assays differ substantially. The Alzheimer’s Association guideline specifically warns that many commercially available blood-based biomarker tests do not meet the performance thresholds recommended for clinical use.

What this means for patients and families

Blood biomarkers are one of the most important changes in Alzheimer’s diagnosis in recent years because they can bring sophisticated biological testing closer to routine clinical practice. For the right patient, a validated test can make it easier to determine whether Alzheimer’s pathology is present and can reduce reliance on more invasive or less accessible procedures.

The most useful way to understand the technology is not as a universal “Alzheimer’s blood test,” but as a new diagnostic tool with defined strengths and limits. The science is strong enough for selected assays to influence real clinical decisions. The interpretation still belongs inside a comprehensive evaluation — because the goal is not simply to detect a protein signal, but to understand what is happening to a person and what should happen next.

---

Related Insights

Selected References

U.S. Food and Drug Administration. FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. May 16, 2025.
U.S. Food and Drug Administration. Class 2 Device Recall: Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio / pTau217 Plasma Calibrators. Recall Z-1303-2026. FDA database updated August 10, 2026.
Alzheimer’s Association. Clinical Practice Guideline on Blood-Based Biomarkers in Alzheimer’s Disease Specialty Care. Released July 29, 2025.
National Institute on Aging. Accurate blood test for Alzheimer’s disease. NIH Research Matters. August 14, 2024.
Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024;332(15):1245–1257.
Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurology. 2024;81(3):255–263.
Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimer’s & Dementia. 2024.

June/16/2026